U.S. Markets close in 59 mins

Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Neurocrine Biosciences Inc (NBIX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Neurocrine Biosciences Inc has a market cap of $7.35 billion; its shares were traded at around $81.05 with a P/E ratio of 1350.84 and P/S ratio of 17.99.


For the last quarter Neurocrine Biosciences Inc reported a revenue of $131.5 million, compared with the revenue of $94.52 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $451.2 million, an increase of 179.2% from last year. For the last five years Neurocrine Biosciences Inc had an average revenue decline of 0% a year. The Neurocrine Biosciences Inc had an operating margin of 8.18%, compared with the operating margin of -81.27% a year before. The 10-year historical median operating margin of Neurocrine Biosciences Inc is -476.51%. The profitability rank of the company is 4 (out of 10).

At the current stock price of $81.05, Neurocrine Biosciences Inc is traded at 55.4% discount to its historical median P/S valuation band of $181.92. The P/S ratio of the stock is 17.99, while the historical median P/S ratio is 40.39. The stock lost 2.05% during the past 12 months.

CEO Recent Trades:

  • CEO Kevin Charles Gorman sold 7,614 shares of NBIX stock on 02/05/2019 at the average price of $88.16. The price of the stock has decreased by 8.06% since.

Directors and Officers Recent Trades:

  • Chief Development Officer Haig P. Bozigian sold 2,725 shares of NBIX stock on 02/05/2019 at the average price of $88.12. The price of the stock has decreased by 8.02% since.
  • Chief Commercial Officer Eric Benevich sold 1,357 shares of NBIX stock on 02/05/2019 at the average price of $88.01. The price of the stock has decreased by 7.91% since.
  • Chief Regulatory Officer Malcolm Lloyd-smith sold 1,272 shares of NBIX stock on 02/05/2019 at the average price of $88.14. The price of the stock has decreased by 8.04% since.
  • Chief Legal Officer Darin Lippoldt sold 1,225 shares of NBIX stock on 02/05/2019 at the average price of $88.09. The price of the stock has decreased by 7.99% since.
  • Chief Research Officer Dimitri E. Grigoriadis sold 2,445 shares of NBIX stock on 02/05/2019 at the average price of $88.14. The price of the stock has decreased by 8.04% since.

For the complete 20-year historical financial data of NBIX, click here.

This article first appeared on GuruFocus.